Over the last 17 years, 119 adult acute myeloid leukemia patients have undergone hematopoietic stem cell transplantation at our Center.
Study Design
Seventy patients in first complete remission received hematopoietic stem cell transplantation (28 allogeneic and 42 autologous HSCT) as late intensification after conventional chemotherapy; 38 patients received allogeneic hematopoietic stem cell transplantation in a more advanced phase. A reference group was built up by collecting 40 acute myeloid leukemia patients who received high-dose cytosine arabinoside as late intensification and whose complete remission lasted more than 10 months.
Results
Results of the study led to conclude that an earlier timing of allogeneic hematopoietic stem cell transplantation can be recommended in order to treat patients who would otherwise suffer an early relapse.
Conclusions
The outcome of autologous hematopoietic stem cell transplantation in patients not in first complete remission supports the possibility of achieving good quality second complete remissions and suggests that autografting may be a life-saving strategy in selected acute myeloid leukemia patients with advanced disease.
FlasshoveM., MeusersP., SchutteJ., NoppeneyR., BeelenD.W., SohrabS., RoggenbuckU., KemmeriesG., BrittingerG., SeeberS., ScheulenM.E.: Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann Hematol, 79: 533–542, 2000.
4.
FeldmanE.J., SeiterK., TraganosF., DarzynkiewiczZ., GoffH., PozzuoliM., BaskindP., SantosS., AhmedT.: Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia. Leuk Lymphoma, 38: 309–315, 2000.
5.
WeickJ.K., KopeckyK.J., AppelbaumF.R., HeadD.R., KingsburyL.L., BalcerzakS.P., BickersJ.N., HynesH.E., WelbornJ.L., SimonS.R., GreeverM.: A randomised investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 88: 2841–2851, 1996.
6.
WiernikP.H., BanksP.L., CaseD.C., ArlinZ.A., PerimanP.O., ToddM.B., RitchP.S., EnckR.E., WeitbergA.B.: Cyatrabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 79: 313–319, 1992.
7.
CahnJ.Y., LabopinM., SierraJ., BlaiseD., ReiffersJ., FerrantA., BergmannL., VisaniG., CornelissenJ., De WitteT., BosiA., FrassoniF., GorinN.C.: No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Br J Haematol, 110: 308–314, 2000.
8.
BishopJ.F., MatthewsJ.P., YoungG.A., SzerJ., GillettA., JoshuaD., BradstockK., EnnoA., WolfM.M., FoxR.: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87: 1710–1717, 1996.
9.
MayerR.J., DavisR.B., SchifferC.A., BergD.T., PowellB.L., SchulmanP., OmuraG.A., MooreJ.O., McIntyreO.R., FreiE.3rd: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med, 331: 896–903, 1994.
10.
CassilethP.A., HarringtonD.P., AppelbaumF.R., LazarusH.M., RoweJ.M., PaiettaE., WillmanC., HurdD.D., BennettJ.M., BlumeK.G., HeadD.R., WiernikP.H.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Eng J Med, 339: 1649–1656, 1998.
11.
BurnettA.K., GoldstoneA.H., StevensR.M., HannI.M., ReesJ.K., GrayR.G., WheatleyK.: Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet, 351: 700–708, 1998.
12.
BurnettA.K., KellJ.: High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia. Curr Opin Oncol, 12: 110–115, 2000.
13.
HarousseauJ.L., CahnJ.Y., PignonB., WitzF., MilpiedN., DelainM., LioureB., LamyT., DesablensB., GuilhotF., CaillotD., AbgrallJ.F., FrancoisS., BriereJ., GuyotatD., CasassusP., AudhuyB., TellierZ., HurteloupP., HerveP.: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood, 90: 2978–2986, 1997.
BurnettA.K., KellJ., RowntreeC.: Role of allogeneic and autologous hematopoietic stem cell transplantation in acute myeloid leukemia. Int J Hematol, 72: 280–284, 2000.
16.
BurnettA.K.: Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults. Cancer Chemother Pharmacol, 48(Suppl 1): S53–S58, 2001.
SungL., BucksteinR., DoyleJ.J., CrumpM., DetskyA.S.: Treatment options for patients with acute myeloid leukaemia with a matched sibling donor: a decision analysis. Cancer, 97: 592–600, 2003.
19.
OosterveldM., SuciuS., VerhoefG., LabarB., BelhabriA., AulC., SelleslagD., FerrantA., WijermansP., MandelliF., AmadoriS., JehnU., MuusP., ZittounR., HessU., AnakO., BeeldensF., WillemzeR., de WitteT.: The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia, 17: 859–868, 2003.
20.
AppelbaumF.R.: Is there a best transplant conditioning regimen for acute myeloid leukemia?Leukemia, 14: 497–501, 2000.
21.
BieriS., HelgC., ChapuisB., MiralbellR.: Total body irradiation before allogeneic bone marrow transplantation: is more dose better?Int J Radiat Oncol Biol Phys, 49: 1071–1077, 2001.
22.
KrögerN., ZabelinaT., SonnenbergS., KrugerW., RengesH., StuteN., FinkensteinF., MayerU., HolsteinK., FiedlerW., ColbergH., SonnenR., KuseR., BraumannD., MetznerB., Del ValleF., ErttmannR., KabischH., ZanderA.R.: Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplatation in patients with acute myeloid leukemia. Bone Marrow Transplant, 26: 711–716, 2000.
23.
RaiolaA.M., Van LintM.T., LamparelliT., GualandiF., MordiniN., BerissoG., BreganteS., FrassoniF., SessaregoM., FugazzaG., Di StefanoF., PittoA., BacigalupoA.: Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplant (HSCT) in patients up to 60 years of age. Br J Haematol, 109: 716–721, 2000.
24.
SociéG., CliftR.A., BlaiseD., DevergieA., RingdenO., MartinP.J., RembergerM., DeegH.J., RuutuT., MichalletM., SullivanK.M., ChevretS.: Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood, 98: 3569–3574, 2001.
25.
LitzowM.R., PerezW.S., KleinJ.P., BolwellB.J., CamittaB., CopelanE.A., GaleR.P., GiraltS.A., KeatingA., LazarusH.M., MarksD.I., McCarthyP.L., MillerC.B., MiloneG., PrenticeH.G., RussellJ.A., SchultzK.R., TriggM.E., WeisdorfD.J., HorowitzM.M.: Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol, 119: 1115–1124, 2002.
26.
ZittounR.A., MandelliF., WillemzeR., de WitteT., LabarB., ResegottiL., LeoniF., DamasioE., VisaniG., PapaG., CaroniaF., HayatM., StryckmansP., RotoliB., LeoniP., PeetermansM.E., DardenneM., VegnaM.L., PettiM.C., SolbuG., SuciuS.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med, 332: 217–223, 1995.
27.
NathanP.C., SungL., CrumpM., BeyeneJ.: Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst, 96: 38–45, 2004.
28.
RohatinerA.Z.S., BassanR., RaimondiR., AmessJ.A.L., ArnottS., PersonenA., RodeghieroF., BarbuiT., BradburnM.J., CarterM., ListerT.A.: High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia. Ann Oncol, 11: 1007–1015, 2000.
29.
LeviI., GrottoI., YerushalmiR., Ben BassatI., ShpilbergO.: Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res, 28: 605–612, 2004.
30.
BrunetS., EsteveJ., BerlangaJ., RiberaJ., BuenoJ., MartìJ., BargayJ., GuardiaR., JuliáA., GranenaA., MontserratE., SierraJ., for the CETLAM Cooperative Group (Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias): Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Haematologica, 89: 940–949, 2004.
31.
BurnettA.K., WheatleyK., GoldstoneA.H., StevensR.F., HannI.M., ReesJ.H., HarrisonG., Medical Research Council Adult, and Paedriatic Working Parties: The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol, 118: 385–400, 2002.
32.
ChalandonY., BarnettM.J., HorsmanD.E., ConneallyE.A., NantelS.H., NevillT.J., NittaJ., ShepherdJ.D., SutherlandH.J., TozeC.L., HoggeD.E.: Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant, 8: 435–443, 2002.
33.
RobinM., GuardiolaP., DombretH., BaruchelA., EsperouH., RibaudP., DevergieA., GluckmanE., SocieG.: Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality. Bone Marrow Transplant, 31: 877–887, 2003.
34.
TallmanM.S., RowlingsP.A., MiloneG., ZhangM.J., PerezW.S., WeisdorfD., KeatingA., GaleR.P., GellerR.B., LaughlinM.J., LazarusH.M., LugerS.M., McCarthyP.L., RoweJ.M., SaezR.A., VowelsM.R., HorowitzM.M.: Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood, 96: 1254–1258, 2000.
35.
CollissonE.A., LashkariA., MaloneR., PaquetteR., EmmanouilidesC., TerritoM.C., SchillerG.J.: Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission. Leukemia, 17: 2183–2188, 2003.
